Business Overview: Artelo Biosciences, Inc. (NASDAQ: ARTL)

---

Executive Summary

Artelo Biosciences, Inc. is a clinical-stage pharmaceutical company developing novel therapeutics that modulate the body's endocannabinoid system and related lipid-signaling pathways to treat conditions including cancer-related pain, chemotherapy-induced side effects, and cancer-associated anorexia/cachexia (severe weight and muscle loss). Rather than pursuing cannabis-derived compounds directly, Artelo's pipeline consists of novel, patent-protected small-molecule and biologic drug candidates designed to selectively target specific receptors and proteins within this signaling system.

Headquartered in Solana Beach, California, Artelo's most advanced programs include candidates targeting fatty acid binding protein 5 (FABP5) for neuropathic and cancer pain, and a cannabinoid receptor-targeted program for cancer-related anorexia/cachexia — both addressing significant unmet needs in oncology supportive care where current treatment options are limited.

---

1. Core Business Model & How They Work

As a clinical-stage biotech, Artelo's value creation model is centered on advancing novel drug candidates through clinical development toward partnership or regulatory approval, rather than current product sales.

[ Endocannabinoid/Lipid Signaling Drug Discovery ] ➡️ [ Preclinical Proof-of-Concept ] ➡️ [ Early Clinical Trials (Ph I/II) ] ➡️ [ Potential Pharma Partnership / Licensing ] ➡️ [ Regulatory Approval & Commercialization (Long-Term) ]

Key Operational Drivers

1. Novel, Patent-Protected Chemistry: Unlike companies simply reformulating cannabis-derived compounds (CBD/THC), Artelo develops proprietary new chemical entities engineered to selectively engage specific targets in the endocannabinoid and lipid signaling pathways, aiming for more precise pharmacology and a stronger patent position.
2. Focus on High-Unmet-Need Oncology Supportive Care: Artelo's lead indications — chemotherapy-induced peripheral neuropathy, cancer pain, and cancer-related anorexia/cachexia — are conditions with few effective approved treatments, representing a differentiated clinical and commercial opportunity if successful.
3. Capital-Efficient Development Model: As a small-cap clinical-stage company, Artelo relies on staged, milestone-driven development and, at points, non-dilutive grant or partnership funding to advance its pipeline without the R&D budget of a large pharmaceutical company.
4. Partnership/Licensing Optionality: Like most small clinical-stage biotechs, Artelo's long-term commercial strategy likely includes potential licensing or partnership deals with larger pharmaceutical companies once clinical proof-of-concept is established, rather than building a full commercial infrastructure independently.

---

2. Pipeline Focus Areas

---

3. Competitive Landscape

Key Competitors

• Large oncology supportive care franchises within major pharmaceutical companies addressing chemotherapy side effects (nausea, pain, neuropathy) with existing approved therapies.
• Other endocannabinoid-system-focused biotechs pursuing novel, patent-protected compounds targeting similar pathways, a small but active area of pharmaceutical research.
• Cachexia/anorexia drug developers more broadly, including companies developing ghrelin agonists, selective androgen receptor modulators, and other mechanisms for cancer-related muscle wasting — a competitive but still underserved therapeutic category.

Dynamics

Chemotherapy-induced neuropathy and cancer cachexia remain areas with very limited approved treatment options, meaning Artelo's competitive position is less about displacing an entrenched incumbent and more about being among the first to demonstrate clinical efficacy that could define a new standard of supportive oncology care, competing against a relatively small number of similarly early-stage developers pursuing different mechanisms for the same unmet needs.

---

4. Strategic Strengths & Moats vs. Strategic Risks

Competitive Strengths (The Moat)

• Proprietary, patent-protected chemical entities rather than reformulated cannabis compounds, supporting stronger intellectual property protection.
• Focus on high-unmet-need indications with limited existing competition from approved therapies.
• Scientific specialization in endocannabinoid/lipid signaling biology developed over years of focused research.

Strategic Risks & Vulnerabilities

1. Early-Stage Clinical & Regulatory Risk: As with all early clinical-stage biotech, Artelo's candidates face substantial binary risk at each clinical trial stage, with no guarantee of eventual approval.
2. Funding/Dilution Risk: Continued clinical development requires ongoing capital, creating typical small-cap biotech financing and shareholder dilution risk.
3. Small Company Scale: Limited internal resources relative to larger pharmaceutical competitors could pursue similar or overlapping mechanisms with greater resources.
4. Commercial Uncertainty: Even with clinical success, the eventual commercial pathway (partnership vs. independent commercialization) and market size for niche oncology supportive care indications carry meaningful uncertainty.

---

5. Financial Overview & Performance Matrix

---

6. Summary Conclusion

Artelo Biosciences occupies a scientifically differentiated niche in endocannabinoid and lipid-signaling drug development, pursuing novel, patent-protected therapeutics aimed at oncology supportive care indications — chemotherapy-induced neuropathy and cancer-related cachexia — where current treatment options remain limited.

The central long-term question, as with any clinical-stage biotech of its size, is clinical execution and funding: Artelo's value depends on generating positive clinical proof-of-concept data in its lead programs sufficient to attract a larger pharmaceutical partner or continued capital markets support, well before the company would need to consider independent commercialization.